[ad_1]
*** PRESS RELEASE *** San Francisco, CA – Herzliya, Israel, August 17, 2021 – Cannformatics, an early-stage biotechnology startup centered on the identification and utility of saliva-based Hashish-Responsive TM biomarkers and Cannabotech, a biomedical firm creating medical options based mostly on botanical mixtures of hashish extracts and practical mushrooms, as we speak introduced that Cannabotech has commissioned Cannformatics to conduct a examine to consider the consequences of Cannabotech’s Cannabo-Nerve mixture on human sufferers affected by persistent neuropathic ache. This examine may also examine “MycoCann NeuroPain” to different main off-the-shelf medical hashish ache relievers which are at present being offered within the state of CA.
“We are honored that Cannabotech chose Cannformatics to scientifically evaluate the impact of “MycoCann NeuroPain”. Pharmacometabolomic knowledge together with examine participant ache assessments are distinctive of their capability to supply insights right into a product’s physiological mechanism of motion and skill to handle persistent ache,” stated Cannformatics CEO and Cofounder, Dr. Itzhak Kurek. “This is an exciting opportunity to support Cannabotech in bringing new hope to patients suffering with chronic neuropathic pain and deepen our understanding of pain related Cannabis-Responsive biomarkers.”
The examine shall be carried out below the supervision of an FDA regulated Institutional Overview Board (IRB) along side Cannformatics’ Advisory Board members Dr. Donald Abrams and Dr. Bonni Goldstein. Topic to receiving IRB approval, Cannformatics will start recruiting members for the examine. Individuals excited by collaborating the examine might join examine updates HERE.
Elchanan Shaked, CEO and Chairman of Cannabotech, stated: “For the past two-years Cannabotech has built a rigorous scientific pipeline for the development of cannabis- and mushroom-based products. The unique formulation that will be tested combines an exact composition of 13 cannabinoids and terpenes with mushroom extracts for the purpose of reducing chronic neuropathic pain without THC-related psychoactive effects. Cannformatics’ technology will provide novel insights obtained in a real-world setting, adding an important layer to the high- quality scientific evidence necessary to gain the support of the medical community ahead of a planned launching of “MycoCann NeuroPain” within the second half of 2022.”
About Cannformatics, Inc:
Cannformatics is an early-stage biotechnology startup centered on the personalization of medical hashish remedy by the identification and utility of Hashish- Responsive™ biomarkers present in saliva. The corporate’s mission is to ship suggestions for predictable and repeatable science-based medical hashish remedy to enhance well being and high quality of life. The corporate is now pursuing figuring out Hashish-ResponsiveTM biomarkers associated to autism spectrum dysfunction in kids.
Cannformatics is headquartered in San Francisco, CA.
About Cannabotech, Inc:
Cannabotech is an Israeli biomedical firm creating botanical options for preventive & integrative medication. These options are based mostly on mixtures of energetic substances from the hashish plant and medicinal mushrooms specializing in two primary programs within the human physique: the endocannabinoid (ECS) system and the immune system. The Firm’s objective is to develop merchandise that may be built-in into current oncology remedy protocols. Cannabotech is creating a collection of eight formulation designed to assist sufferers affected by 5 most cancers varieties (Pancreatic, Colorectal, Breast, Lung & Prostate), and reduce chemotherapy-induced chemotherapy-induced neuropathic ache (CINP) and chemotherapy-induced nausea and vomiting (CINV).
Cannabotech is headquartered in Herzliya, Israel.
*** END OF PRESS RELEASE ***
